Sidharth Mehan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7197843/publications.pdf

Version: 2024-02-01

67	1,354	430874	414414
papers	citations	18 h-index	32 g-index

72	72	72	1072
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Understanding Abnormal SMO-SHH Signaling in Autism Spectrum Disorder: Potential Drug Target and Therapeutic Goals. Cellular and Molecular Neurobiology, 2022, 42, 931-953.	3.3	20
2	Targeting Abnormal PI3K/AKT/mTOR Signaling in Intracerebral Hemorrhage: A Systematic Review on Potential Drug Targets and Influences of Signaling Modulators on Other Neurological Disorders. Current Reviews in Clinical and Experimental Pharmacology, 2022, 17, 174-191.	0.8	11
3	Guggulsterone Mediated JAK/STAT and PPAR-Gamma Modulation Prevents Neurobehavioral and Neurochemical Abnormalities in Propionic Acid-Induced Experimental Model of Autism. Molecules, 2022, 27, 889.	3.8	26
4	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. Current Medical Science, 2022, , 1.	1.8	4
5	Neuroprotective Effect of Chrysophanol as a PI3K/AKT/mTOR Signaling Inhibitor in an Experimental Model of Autologous Blood-induced Intracerebral Hemorrhage. Current Medical Science, 2022, 42, 249-266.	1.8	11
6	Protective effects of apigenin on methylmercury-induced behavioral/neurochemical abnormalities and neurotoxicity in rats. Human and Experimental Toxicology, 2022, 41, 096032712210842.	2.2	26
7	Activation of SIRT-1 Signalling in the Prevention of Bipolar Disorder and Related Neurocomplications: Target Activators and Influences on Neurological Dysfunctions. Neurotoxicity Research, 2022, 40, 670-686.	2.7	5
8	Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration. Degenerative Neurological and Neuromuscular Disease, 2022, Volume 12, 31-59.	1.3	11
9	Smo-Shh Agonist Purmorphamine Prevents Neurobehavioral and Neurochemical Defects in 8-OH-DPAT-Induced Experimental Model of Obsessive-Compulsive Disorder. Brain Sciences, 2022, 12, 342.	2.3	16
10	Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions. Molecular Neurobiology, 2022, 59, 3888-3912.	4.0	15
11	Effect of alpha-mangostin in the prevention of behavioural and neurochemical defects in methylmercury-induced neurotoxicity in experimental rats. Toxicology Reports, 2022, 9, 977-998.	3.3	17
12	Mechanisms of Mitochondrial Malfunction in Alzheimerâ€™s Disease: New Therapeutic Hope. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-28.	4.0	16
13	Involvement of Phytochemical-Encapsulated Nanoparticlesâ€™ Interaction with Cellular Signalling in the Amelioration of Benign and Malignant Brain Tumours. Molecules, 2022, 27, 3561.	3.8	5
14	PI3K/AKT/mTOR signalling inhibitor chrysophanol ameliorates neurobehavioural and neurochemical defects in propionic acid-induced experimental model of autism in adult rats. Metabolic Brain Disease, 2022, 37, 1909-1929.	2.9	15
15	Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity. Molecules, 2022, 27, 3878.	3.8	17
16	Polyphenols Targeting and Influencing Cellular Signaling During Progression and Treatment of Cancer. , 2021, , 95-141.		0
17	Involvement of adenylate cyclase/cAMP/CREB and SOX9/MITF in melanogenesis to prevent vitiligo. Molecular and Cellular Biochemistry, 2021, 476, 1401-1409.	3.1	13
18	Green Nanoparticles: A Hope for Targeted Delivery of Natural Therapeuticals for the Management of Glioblastoma Multiforme (GBM). , 2021, , 397-437.		0

#	Article	IF	Citations
19	Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders. CNS and Neurological Disorders - Drug Targets, 2021, 20, 417-429.	1.4	10
20	Guggulsterone ameliorates ethidium bromide-induced experimental model of multiple sclerosis via restoration of behavioral, molecular, neurochemical and morphological alterations in rat brain. Metabolic Brain Disease, 2021, 36, 911-925.	2.9	33
21	Neuroprotective Effect of Î±-Mangostin in Ameliorating Propionic Acid-Induced Experimental Model of Autism in Wistar Rats. Brain Sciences, 2021, 11, 288.	2.3	40
22	Neuroprotective Methodologies in the Treatment of Multiple Sclerosis Current Status of Clinical and Pre-clinical Findings. Current Drug Discovery Technologies, 2021, 18, 31-46.	1.2	14
23	Connection between JAK/STAT and PPARÎ³ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain. Current Molecular Pharmacology, 2021, 14, 823-837.	1.5	18
24	Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 1845-1868.	1.2	15
25	Smo-Shh signaling activator purmorphamine ameliorates neurobehavioral, molecular, and morphological alterations in an intracerebroventricular propionic acid-induced experimental model of autism. Human and Experimental Toxicology, 2021, 40, 1880-1898.	2.2	28
26	Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions. Neurological Sciences, 2021, 42, 3145-3166.	1.9	20
27	Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats. Current Bioactive Compounds, 2021, 17, .	0.5	18
28	Nrf2/HO-1 Signaling Activator Acetyl-11-keto-beta Boswellic Acid (AKBA)-Mediated Neuroprotection in Methyl Mercury-Induced Experimental Model of ALS. Neurochemical Research, 2021, 46, 2867-2884.	3.3	34
29	Current Neuropharmacological Interventions in Autism: Potential Drug Targets from Pre-clinical and Clinical Findings. Current Psychopharmacology, 2021, 10, 98-114.	0.3	0
30	Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism. Current Drug Targets, 2021, 22, 1071-1086.	2.1	5
31	Targeting PI3K-AKT/mTOR signaling in the prevention of autism. Neurochemistry International, 2021, 147, 105067.	3.8	49
32	Neuroprotective efficacy of 4-Hydroxyisoleucine in experimentally induced intracerebral hemorrhage. Saudi Journal of Biological Sciences, 2021, 28, 6417-6431.	3.8	15
33	Exploring Molecular Approaches in Amyotrophic Lateral Sclerosis: Drug Targets from Clinical and Pre-Clinical Findings. Current Molecular Pharmacology, 2021, 14, 263-280.	1.5	10
34	Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases. Neurotoxicity Research, 2021, 39, 1630-1650.	2.7	15
35	Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions. European Journal of Cell Biology, 2021, 100, 151179.	3.6	12
36	Targeting Nrf2/HO-1 anti-oxidant signaling pathway in the progression of multiple sclerosis and influences on neurological dysfunctions. Brain Disorders, 2021, 3, 100019.	1.7	20

#	Article	IF	Citations
37	Possible Therapeutic Interventions in COVID-19 Induced ARDS by Cotinine as an ACE-2 Promoter and AT-1R Blocker. Infectious Disorders - Drug Targets, 2021, 21, e170721189261.	0.8	3
38	Neuroprotection by solanesol against ethidium bromide-induced multiple sclerosis-like neurobehavioral, molecular, and neurochemical alterations in experimental rats. Phytomedicine Plus, 2021, 1, 100051.	2.0	26
39	Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders. Current Molecular Medicine, 2021, 21, 630-644.	1.3	13
40	Inhibition of c-JNK/p38MAPK signaling pathway by Apigenin prevents neurobehavioral and neurochemical defects in ethidium bromide-induced experimental model of multiple sclerosis in rats: Evidence from CSF, blood plasma and brain samples. Phytomedicine Plus, 2021, 1, 100139.	2.0	16
41	Design, synthesis and neuropharmacological evaluation of new 2,4-disubstituted-1,5-benzodiazepines as CNS active agents. Bioorganic Chemistry, 2020, 101, 104010.	4.1	24
42	Neuroprotective potential of solanesol in a combined model of intracerebral and intraventricular hemorrhage in rats. IBRO Reports, 2020, 8, 101-114.	0.3	36
43	Investigation of Low Dose Cabazitaxel Potential as Microtubule Stabilizer in Experimental Model of Alzheimer's Disease: Restoring Neuronal Cytoskeleton. Current Alzheimer Research, 2020, 17, 601-615.	1.4	14
44	Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats. Neural Regeneration Research, 2020, 15, 1140.	3.0	38
45	Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies. Current Signal Transduction Therapy, 2020, 15, 197-204.	0.5	0
46	Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings. Journal of Alzheimer's Disease Reports, 2019, 3, 179-218.	2.2	16
47	Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. Toxicology Reports, 2019, 6, 1164-1175.	3.3	48
48	Understanding multifactorial architecture of Parkinsonâ€™s disease: pathophysiology to management. Neurological Sciences, 2019, 40, 13-23.	1.9	67
49	Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings. CNS and Neurological Disorders - Drug Targets, 2019, 18, 446-465.	1.4	10
50	Myocardial Preconditioning Potential of Hedgehog Activator Purmorphamine (Smoothened Receptor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Journal of Pharmacology and Pharmacotherapeutics, 2019, 10, 47-56.	0.4	7
51	Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction. Indian Journal of Pharmacology, 2018, 50, 309.	0.7	44
52	Forskolin, ameliorates mitochondrial dysfunction in Streptozotocin induced diabetic nephropathy in rats. Asian Journal of Pharmacy and Pharmacology, 2018, 5, 199-206.	0.1	1
53	Role of adenylyl cyclase activator in controlling experimental diabetic nephropathy in rats. International Journal of Physiology, Pathophysiology and Pharmacology, 2018, 10, 144-153.	0.8	1
54	Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinsonâ€™s disease: a Complete Review. , 2017, 1, 001-026.		8

#	Article	IF	Citations
55	Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders. Neural Regeneration Research, 2017, 12, 290.	3.0	39
56	Clinical Therapeutic Strategies to Ameliorate the Mitochondrial ETC Complexes Dysfunctions in Autism: First Time from India. Virology & Immunology Journal, 2017, 1, .	0.1	0
57	Experimental evidence for the potential of lycopene in the management of scopolamine induced amnesia. RSC Advances, 2015, 5, 72881-72892.	3.6	27
58	Polyphenol Ellagic Acid-Targeting To Brain: A Hidden Treasure. International Journal of Neurology Research, 2015, 1, 141-152.	0.2	12
59	Precautionary Ellagic Acid Treatment Ameliorates Chronically Administered Scopolamine Induced Alzheimer's Type Memory and Cognitive Dysfunctions in Rats. Pharmacologia, 2015, 6, 192-212.	0.3	5
60	Renoprotective Effect of Ace Inhibitor-Lisinopril and Heme Oxygenase-1 Inducer-Hemin Combination against Streptozotocin Induced Advanced Diabetic Nephropathy in Rats. Pharmacologia, 2014, 5, 60-75.	0.3	1
61	Boswellia serrata-frankincense (A Jesus Gifted Herb); An Updated Pharmacological Profile. Pharmacologia, 2013, 4, 457-463.	0.3	12
62	Spices, Fruits, Nuts and Vitamins: Preventive Interventions for Myocardial Infarction. Pharmacologia, 2013, 4, 553-570.	0.3	3
63	Cellular Signals like MAPK/NF-kB/m-TOR Mediated Drug Resistance: A Promising Concept in Cancer Research. Pharmacologia, 2013, 4, 414-427.	0.3	0
64	Dementia â€“ A Complete Literature Review on Various Mechanisms Involves in Pathogenesis and an Intracerebroventricular Streptozotocin Induced Alzheimerâ€™s Disease. , 2012, , .		6
65	JNK: A Stress-Activated Protein Kinase Therapeutic Strategies and Involvement in Alzheimerâ€™s and Various Neurodegenerative Abnormalities. Journal of Molecular Neuroscience, 2011, 43, 376-390.	2.3	136
66	Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine â€” a PDE1 inhibitor. European Journal of Pharmacology, 2009, 620, 49-56.	3.5	151
67	Neuroprotective Strategies of Blood-Brain Barrier Penetrant â€œForskolinâ€• (AC/cAMP/PK_A/CREB Activator) to Ameliorate Mitochondrial Dysfunctioning in Neurotoxic Experimental Model of Autism. , 0, , .		5